• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
CADD and Informatics Services

CADD and Informatics Services

We provide wide range of standalone and integrated CADD & Informatics services to enable candidate progression at every stage of the program.

We follow a holistic approach to discovery projects by studying the target of interest and the different pathways. We have standardized procedures and highly-skilled scientists for solving complex problems related to discovery. The CADD facility routinely supports discovery projects starting from target identification to clinical positioning of the candidate compound. We have a wide range of tools available for compound optimization. Also, we have proven expertise in collaborative small molecule, PROTAC and peptide drug discovery projects.

Speak to our experts

Various Techniques and Tools, CADD & Informatics

Virtual Screening

Virtual screening is a powerful modeling technique to identify novel hit compounds in any discovery program. It is routinely deployed in drug discovery projects for compound ideation and conceptualization. Virtual screening has multiple applications including hit scouting and hit-to-lead optimization.

The techniques deal with computational or in silico analog of biological screening to score, rank, and/or filter a set of structures using one or more computational procedures. This helps to decide which compounds to screen, which libraries to synthesize, and which compounds to purchase from an external source. Virtual screening uses both structures, ligand or compound-guided computational methods, or a combination of both.

We have access to more than two billion commercially available compounds’ databases. This database is routinely used to carry out virtual screening studies to facilitate the compound design and ideation.

Structure-based Design Approach

Structure-based design approach exploits disease-related targets by experimentally determining 3-dimensional structure (e.g. X-ray, NMR, or Cryo-EM) or homology model (in case of unavailability of experimental structure). This method is performed to predict the binding pose of the molecule in the binding site and estimate probable binding affinity or a score representing the strength of binding.

We use docking and molecular dynamics simulation to shortlist compounds that may become a good hit or lead for a project.

Ligand-based Design Approach

Ligand or compound-based design is another powerful modeling technique used in CADD. Some of the most used techniques routinely deployed at Aurigene include pharmacophore modeling, quantitative structure-activity relationship (QSAR), or knowledge-based expert methods, for compound design and ideation. We use a ligand-based design approach in de novo, scaffold hopping, ligand hybridization, fragment-linking and related techniques. The ligand-based approach is not limited to compound designs but is also deployed in a predictive model. Predictive models built using AI/ML techniques are used at our facility to determine compound potency, selectivity and Physico-chemical properties. This in turn facilitates project progress.

Tools and Software

Our CADD and bioinformatics facility are equipped with a state-of-the-art “Nanome” interactive virtual reality platform. This is supplemented by the acclaimed "MolSoft" commercial suite of software to carry out all modeling studies. Additionally, our team uses open-source CADD-related software (e.g. KNIME, Cytoscape and Datawarrior) to enrich modeling and simulation-related work. We use a public-domain database to enrich our understanding of disease biology and chemical space. Our facility is equipped with a high-end workstation to cater to the need for CPU/GPU intensive simulation and AI/ML-related activity.

Why Aurigene Pharmaceutical Services?

3-D virtual reality facility

High-end software for simulation & modelling (MolSoft)

Team lead by domain expert in CADD and Informatics

Other Services

Virtual Tour

 

Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Resources

resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
View All
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
View All
resourceMainImage

Carbohydrate

...

Read More
View All
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack